| Item Type | Name |
|
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
|
Concept
|
Drug Therapy, Combination
|
|
Concept
|
Chemotherapy, Adjuvant
|
|
Academic Article
|
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.
|
|
Academic Article
|
A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer.
|
|
Academic Article
|
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
|
|
Academic Article
|
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
|
|
Academic Article
|
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
|
|
Academic Article
|
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
|
|
Academic Article
|
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
|
|
Academic Article
|
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.
|
|
Academic Article
|
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
|
|
Academic Article
|
ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncology-breast.
|
|
Academic Article
|
Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group.
|
|
Academic Article
|
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer.
|
|
Academic Article
|
Other options in the treatment of advanced breast cancer.
|
|
Academic Article
|
Adjuvant endocrine therapy for breast cancer.
|
|
Academic Article
|
Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial.
|
|
Academic Article
|
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
|
|
Academic Article
|
Cardiovascular Monitoring With Trastuzumab Therapy: How Frequent Is Too Frequent?
|
|
Academic Article
|
Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation.
|
|
Academic Article
|
Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer.
|
|
Academic Article
|
Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.
|
|
Academic Article
|
Hormone replacement therapy and nonhormonal control of menopausal symptoms in breast cancer survivors.
|
|
Academic Article
|
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
|
|
Academic Article
|
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
|
|
Academic Article
|
A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer.
|
|
Academic Article
|
American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.
|
|
Academic Article
|
Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs.
|
|
Academic Article
|
De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
|
|
Academic Article
|
Endodermal sinus tumor of the mediastinum.
|
|
Academic Article
|
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry.
|
|
Academic Article
|
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer.
|
|
Academic Article
|
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease.
|